Abstract: An analgesic cosmetic formulation in the form of an ointment, salve or cream which is applied to the skin, including the hands and feet for the treatment of such conditions as redness, swelling, itching and soreness of the skin. The cosmetic formulation contains ingredients including oranges, avocado, watermelon, banana, lemon, palm oil, coconut oil, petroleum jelly, beeswax, aloe vera, vitamin E, aspirin, ammonium sulfate, sodium bisulfate and quine sulfate.

Abstract: An improved method of treating psoriasis involves controlling the enhanced proliferation and terminal differentiation of psoriatic epidermis through the activity of epidermal phosphorylase kinase. In general, the method involves contacting psoriatic epidermal cells with a combination of substances affecting the activity of phosphorylase kinase. The combination can be: (1) a calmodulin inhibitor together with a stimulator of cAMP-dependent protein kinase II, (2) a calmodulin inhibitor together with a calcium channel blocker; (3) a stimulator of cAMP-dependent protein kinase II together with a calcium channel blocker; or (4) a calmodulin inhibitor together with a calcium channel blocker and a stimulator of cAMP-dependent protein kinase II. Alternatively, a selective phosphorylase kinase inhibitor such as curcumin can be administered, alone or with an agent such as vitamin D.sub.3 or an analogue thereof, etretinate, diltiazem, or anthralin. The invention also includes pharmaceutical compositions.

Abstract: The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from the gel to the skin condition.

Abstract: Polypeptides derived from human interleukin-8 (IL-8) or other alpha chemokines which act as anti-inflammatory agents for the therapy of autoimmune disease, inflammatory conditions, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

Abstract: The present invention provides compositions comprising talc, silkworm excrement, and ingredients of plants of species of the genera Stephania, Coix, Pinellia, Prunus, Phellodendron, Sophora, Tetrapanax, Stemona, Glycyrrhiza, Tripterygium, Forsythia and Siegesbeckia, wherein such compositions have analgesic, antipyretic, and antiinflammatory properties. The present invention also provides methods of using such compositions for treating various diseases, including osteoarthritis and rheumatoid arthritis.

Abstract: The present invention is a topical film-forming composition comprising; (a) a non-toxic volatile solvent, (b) a cellulosic material having at least one hydroxyl group on a side chain of a cellulose backbone, (c) an esterification agent capable of reacting with said hydroxyl group on the side chain of said cellulosic material to form an ester, and (d) a glycerol monolaurate crosslinking agent. Various medicinal, antibiotic, anitfungal, anesthetic, analgesic and virucidal agents may be included within the composition.

Abstract: Topically applicable pharmaceutical/dermatological/cosmetic compositions, well suited for the therapeutic treatment of neurogenic red skin blotches and rosacea afflicting the skin, scalp and/or mucosae of a human subject, comprise a therapeutically/cosmetically effective amount of at least one TNF-alpha antagonist.

Abstract: The present invention relates to intercellular adhesion molecules (ICAM-3) which is involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes therapeutic and diagnostic uses for adhesion molecules and for the antibodies that are capable of binding them.

Abstract: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.

Abstract: The use of carotenoids for producing drugs for the treatment of inflammatory disorders not caused by the action of light or an infection with microorganisms.

Abstract: A method of treating or preventing hypertrophic scar tissue in human skin comprising applying topically an effective amount of a non-toxic amine compound that is a transglutaminase inhibitor having a free amino group is disclosed. The amine compound that is a transglutaminase inhibitor is also selective for inhibiting Type III collagen peptide cross-linking.

Abstract: Disclosed is a topical composition for relieving pain in a person in need of such relief, consisting essentially of an effective amount of a combination of at least one corticoid analgesic, at least one arylpropionic acid type analgesic, and at least one p-aminobenzoic acid ester type local anesthetic; an amount effective in enhancing the effectiveness in relieving pain of the combination of capsaicin, and an amount effective to increase the transmission thereof of through the skin of at least one phospholipid and at least one polyoxyethylenepolyoxypropylene copolymer.

Abstract: The present invention relates to novel colchicine derivatives having antiproliferative, antineoplastic, antiinflammatory and muscle relaxant activities; said derivatives include novel colchine nitrogen amides for use either as such or after derivatization of the hydroxyl at C.sub.3 of the aromatic ring and at C.sub.10 of the tropolone ring. These novel compounds have a cytotoxicity on human tumoral cell lines comparable with colchicine but, in comparison with the latter, they are much more active on cells resistant to the usual antiblastics. The compounds can be included in pharmaceutical formulations useful for the intravenous, oral and topical administrations.

Abstract: This invention is a composition and a method for treating animal skin ailments by a topical application of the composition to the animal in which the composition is a liquid or gel having potassium formate, sodium formate, or cesium formate in water in an effective concentration. Typically, the skin ailments treated are those caused by pyotraumatic dermatitis, chronic itching, scratching and chewing, and flea and insect bites in dogs, cats, horses and other animals.

Abstract: Novel compounds of formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each selected from hydrogen and fluoro and at least one and not more than two is fluoro;R.sup.5 is selected from hydrogen and C.sub.1 -C.sub.4 alkyl;R.sup.6 is selected from hydrogen, C.sub.1 -C.sub.4 ally and hydroxy; orR.sup.5 and R.sup.6 together with the ring carbon form a carbonyl group;R.sup.7 is selected from hydrogen and hydroxy,R.sup.8 and R.sup.9 are each selected from hydrogen, C.sub.1 -C.sub.4 alkyl and cyclo(C.sub.3 or C.sub.4) alkyl or together with the nitrogen form a morpholino group; andX is selected from a bond, methylene and --O-- and is always a bond or --O-- when any of R.sup.5, R.sup.6 and R.sup.7 is other than hydrogen and is always a bond when R.sup.5 and R.sup.6 together with the ring carbon form a carbonyl group;and their salts and solvates have a number of uses as central muscle relaxants. In particular, treatment of conditions associated with abnormally raised skeletal muscle tone.

Abstract: An anti-hemorrhoidal composition, tea, and kit containing tea bags including, in combination, a first herb of the genus Equisetaceae and a second herb of the Generie Juliania, family Julianiaceae, genus Amphipterygium adstringens (also known as "Cuachalalate.") is provided herein. Further provided herein is a method of treating hemorrhoids and a method for making an anti-hemorrhoidal composition.

Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.

Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and anti-inflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.

Abstract: The invention relates to the use of metronidazole, or preferably of a combination of metronidazole and clindamycin, as active principle for the manufacture of pharmaceutical compositions, more particularly dermatological compositions, intended for an anti-inflammatory treatment by the topical route.

Abstract: Chemical compositions for the treatment of bovine mastitis which compositions are combinations of four components i.e.; Echinechea Goldenseal Supreme; Wild Ginseng Supreme; gelsemium, pokeroot, and aconite; and aloe vera juice, which form a dose which is injected into the mastitis affected portion of a cow's udder for a minimum of two doses per day for at least three days, which results in a cure for the mastitis.

Abstract: A series of new azulene derivatives are disclosed, which are represented by the following formula; ##STR1## wherein: R.sub.1 is hydrogen atom, lower alkoxycarbonyl group, carboxy group, halogen atom, lower alkyl group, phenyl group or lower alkanoyl group; R.sub.2, R.sub.3 and R.sub.4 are hydrogen atom, lower alkyl group, lower alkoxy group or halogen atom; X is lower alkyl group or amino group.The compounds of the present invention are useful for treatment of inflammation.

Abstract: A composition for use in immunosuppression therapy is disclosed. The composition includes an immunosuppressant drug, such as cyclosporin A, and an ethanol extract of the root xylem of Tripterygium wilfordii. The extract is effective alone, or in combination with such an immunosuppressant, in the treatment of transplantation rejection. Also disclosed is a method of immunosuppression that includes administering to a subject a pharmaceutically effective amount of an immunosuppressant drug and an extract of the type above, in an amount effective to potentiate the action of the drug.

Abstract: A composition for a topically healing ointment having all natural herbs and an animal fat base. The combination of which forms a salve that is active against one or a combination of sources of viral, bacterial and fungus infections that have the ability to penetrate beneath the epidermal layer of the skin.

Abstract: Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein Y is selected from halogen, alkyl, and haloalkyl; n is 0, 1, 2, or 3; A is selected from (a) optionally substituted alkylene, (b) optionally substituted cycloalkylene, (c) optionally substituted cycloalkylene wherein one or two of the carbon atoms is replaced with one or two heteroatoms independently selected from O, S, and N, (d) optionally substituted alkenylene and (e) ##STR2## X is absent or is alkylene; Z is selected from (a) hydrogen, (b) COM wherein M is selected from --OR.sup.4, --NR.sup.6 R.sup.7, and a pharmaceutically acceptable metabolically cleavable group, (c) --OR.sup.2, (d) tetrazolyl, (e) --CH(OR.sup.2)--CH.sub.2 OR.sup.8, (f) --CH(OR.sup.2)--CH.sub.2 --CH.sub.2 OR.sup.8, (g) --CH(OR.sup.2)--CH(OR.sup.8)--CH.sub.2 OR.sup.9, and (h).dbd.N--OR.sup.2 ; and R.sup.

Abstract: A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.

Abstract: The present invention provides a method for treating a lipid body-mediated condition, such as inflammation or cancer, in an vertebrate by administering to the vertebrate a sufficient amount of an agent which inhibits the formation of lipid bodies in cells involved in inflammation. The agent can inhibit lipid body formation by inhibiting any biological activity necessary for lipid body formation.Another embodiment of the present invention is a method or assay for assessing the ability of a compound to inhibit lipid body formation in cells in vitro. The method comprises the steps of priming the cells for lipid body formation, contacting the cells with the compound under study, and comparing lipid body numbers in the cells with lipid body numbers in primed cells not contacted with the compound of interest. This method can be automated, yielding an efficient high-throughput assay for the efficient and rapid screening of large numbers of potential anti-inflammatory drugs.

Abstract: Disclosed are compounds, compositions and methods for inhibiting interleukin-1.beta. protease activity, the compounds having the formula A described herein.

Abstract: The analgesic effectiveness of an NSAID is significantly enhanced by administering the NSAID prior to, with or following the administration of an analgesia enhancer which is a nontoxic NMDA receptor blocker and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation.

Abstract: The invention provides compounds which are useful as inhibitors of matrix metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I) ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are described in the claims, a stereoisomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, ester acyloxyamide, imide or derivative thereof.Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by matrix metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

Abstract: The present invention relates to the use of hymenoptera venom or proteinaceous or polypeptide components contained therein in the manufacture of a medicament for treating DNA virus infections, and to a method for the treatment of mammalian DNA virus infections which uses hymenoptera venom or proteinaceous or polypeptide components contained therein.

Abstract: The present invention relates to a method of treating various diseases and conditions which are dependent on cyclic nucleotide pathways with purified stem bromelain protease. Administration of isolated and purified stem bromelain protease is effective in the treatment of diseases and conditions including inflammation, atherosclerosis, cancer, and bacterial infections.

Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.

Abstract: Methods of preventing tissue damage associated with decreased blood flow in a human by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 .mu.g/ml and 20 .mu.g/ml of AICA riboside for a time sufficient to reduce the risk of said tissue damage in said human. Methods of preventing an adverse clinical outcome, such as an adverse cardiovascular and/or cerebrovascular event, in a patient at risk for such outcome by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 .mu.g/ml and 20 .mu.g/ml of AICA riboside for a time sufficient to reduce the risk for said patient.

Abstract: A composition for treating acne and related skin conditions which contains salicylic acid and aloe vera which is improved by the addition of an effective amount of a methylxanthine. Preferably, the methylxanthine is derived from mate extract. A method for treating acne with the composition is also provided.

Abstract: A method of administering a medicinal agent and an effective amount of a form of hyaluronic acid for decreasing side effects associated with using the agent alone in treating a disease or condition in mammals is disclosed. The agent may be a non-steroidal anti-inflammatory drug (NSAID). The amount of hyaluronic acid is sufficient enough to provide a dosage greater than 200 mg/70 kg person. The molecular weight of the form of hyaluronic acid may be less than 750,000 daltons.

Abstract: A method for increasing the number of capillaries in damaged skin during healing of the skin is disclosed. The method includes the application of a skin composition to the damaged skin which comprises an active compound having peripheral vasokinetic activity and a pharmaceutically acceptable carrier. The active compound is selected from compounds such as Amni visnaga coumarins, Vinca alkaloids, Ergot alkaloids, polyunsaturated fatty acid derivatives, a buflomedil bioflavinoid, Ginkgo bioflavonoids, and Cratageus bioflavonoids. The composition is applied in amount to increase the number of capillaries in new tissue which forms during healing of the damaged skin. Furthermore, a method of treating bedsores is also disclosed.

Abstract: There is disclosed a pharmaceutical composition comprising 1-(5-oxohexyl)-3-methylxanthine in admixture with a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is useful for treating an immune disorder. There is also disclosed a method to modulate the response of a target cell to a stimulus, which method comprises contacting said cell with an amount of 1-(5-oxohexyl)-3-methylxanthine or a pharmaceutical composition thereof, wherein said amount effects a diminution in elevated levels of unsaturated, non-arachidonate phosphatidic acid (PA) and diacylglycerol (DAG) derived from said PA in said cells wherein said elevated levels are stimulated by an agent capable of elevating levels of said PA and said DAG, said diminution being equal to or greater than the diminution effected by treating said cells with pentoxifylline (PTX) at a concentration of 0.5 mmol, thereby modulating the response of said target cell.

Abstract: The present invention provides therapeutic conjugates which comprise a therapeutic compound bound to one to three acyl groups derived from fatty acids. The therapeutic compounds are preferably non.about.steroidal anti.about.inflammatory agents which include a carboxylic acid group. The compounds involve the use of tromethamine or ethanolamine derivative to link the acyl groups derived from fatty acids to the therapeutic compounds.

Abstract: Pharmaceutical preparations for the local treatment of inflammations are claimed herein, characterized in that they contain as the active ingredient one or two compounds of general Formula I ##STR1## wherein X is an oxygen atom or a methylene group,R.sub.1 and R.sub.2 represent a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally interrupted by an oxygen atom,R.sub.3 is a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally substituted by an oxo group, andR.sub.4 is a hydrogen atom or an alkyl group of maximally four carbon atoms.

Abstract: Variously pure ribosomal fractions separated from at least one nonphotosynthetic filamentous bacterium are well suited for formulation into a variety of cosmetic/pharmaceutical compositions, for example for the immunostimulation of the immune system of the skin.

Abstract: In accordance with the present invention, a comfort strip for a razor is provided which topically applies one or more alpha-hydroxy acids or derivatives thereof to the skin surface being shaved. In the preferred practice of the invention, the alpha-hydroxy acid or derivative thereof is incorporated within the water-soluble phase of a comfort strip affixed to a wet shave razor which allows for direct delivery to the skin during the wet shaving process.

Abstract: A cosmetic or dermatological composition containing a mixture of at least one type-III ceramide in the form of a single stereoisomer and of at least one type-V ceramide. This mixture is in particular a mixture having a melting point which is much lower than that of the type-III ceramide. This composition is intended in particular for moisturizing dry skins.

Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Abstract: Disclosed are topical anti-inflammatory compositions containing 0.1% to 10% by weight of a monogalactosyl dieicosapentaenoyl glycerol having esterified eicosapentaenoic acid residues (MGDG-EPA); anti-inflammatory compositions are formulated using a purified microalgal lipid preparation containing 30% to 100% by weight of MGDG-EPA; methods of making the microalgal lipid preparation; methods of treating inflammation by administering the topical anti-inflammatory compositions to a subject in need thereof.

Abstract: A diarylheptanoide derivative of the following formula (1), ##STR1## and a drug composition comprising this compound, such as a 5-lipoxygenase inhibitor, an antiinflammatory agent, and the like. The diarylheptanoide derivative (1) is effective for treating and preventing various inflammatory diseases due to its strong 5-lipoxygenase inhibiting effect.

Abstract: Water-soluble nimesulide salt consisting of the product of reaction of nimesulide and of L-lysine and its preparation, aqueous solution containing it, nimesulide-based combinations with cyclodextrins and their uses.

Abstract: The present invention relates to the area of pharmacology; its objective is to solve the technical problem of inflammation, pain, pruritus and local hyperthermia in human beings and animal species. The composition and the subcompositions thereof are obtained from plants of the family Cactaceae, the main methodological steps being a set of processes: production, purification, physicochemical quantification, biotherapeutic evaluation, biopharmaceutical formulation and molecular identification. From the molecular identification a set of molecules is recognized, comprising carbohydrates and an aromatic amine, the general formulae of which are:C.sub.5 H.sub.10 O.sub.5 (RIBOSE),C.sub.6 H.sub.12 O.sub.5 (FUCOSE),C.sub.6 H.sub.12 O.sub.6 (GALACTOSE; MANNOSE; GLUCOSE),C.sub.8 H.sub.11 O.sub.2 N (1-HYDROXY-1-(4-HYDROXYPHENYL)-2-AMINOETHANE),C.sub.10 H.sub.18 O.sub.9 (RIBOFURANOSYLRIBOSE).

Abstract: The present invention relates to a ketoprofen liposome gel and a process for its preparation which is distinguished by a simple method of preparation by spontaneous formation of liposomes from phospholipids and ketoprofen.

Abstract: The invention relates to a phytotherapeutic agent for the treatment of skin lesions and morbid skin changes. In particular, it should be suitable for functioning as an effective therapeutic agent for the treatment of herpes simplex without significant side effects.The phytotherapeutic agent consists of an extract of components extractable from sage, (Salvia officinalis), ribwort plantain (Plantago lanceolata), greater plantain (Plantago major) and mistletoe (Viscum album).